September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Long term visual outcomes in ranibizumab non-responders: patients with neovascular age-related macular degeneration switched from ranibizumab to aflibercept
Author Affiliations & Notes
  • Farid Afshar
    Ophthalmology, Cheltenham General Hospital, Eastleigh, United Kingdom
  • Emily Fletcher
    Ophthalmology, Cheltenham General Hospital, Eastleigh, United Kingdom
  • Quresh Mohamed
    Ophthalmology, Cheltenham General Hospital, Eastleigh, United Kingdom
  • Rob Johnston
    Ophthalmology, Cheltenham General Hospital, Eastleigh, United Kingdom
  • Footnotes
    Commercial Relationships   Farid Afshar, None; Emily Fletcher, None; Quresh Mohamed, None; Rob Johnston, Medisoft (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 520. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Farid Afshar, Emily Fletcher, Quresh Mohamed, Rob Johnston; Long term visual outcomes in ranibizumab non-responders: patients with neovascular age-related macular degeneration switched from ranibizumab to aflibercept. Invest. Ophthalmol. Vis. Sci. 2016;57(12):520.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report visual outcomes in eyes with neovascular age-related macular degeneration (nAMD) switched from treatment with ranibizumab to aflibercept.

Methods : Data was collected prospectively using an electronic patient record system. Patients with nAMD with persistent fluid after a minimum of 5 ranibizumab injections in 6 months, in addition to 3 loading doses, were switched to aflibercept. Eyes were initially treated with a pro re nata regimen. After switching eyes had a loading phase of 3 aflibercept injections at monthly intervals and fixed injections initially at 2 month intervals followed by a treat and extend regimen, with an 18 month follow up.

Results :
Mean visual outcomes in 254 eyes. Prior to switching the visual acuity declined from a mean of 63.6 letters to 58.7 letters when switched. After 18 months of treatment with aflibercept the mean visual acuity was 55.3 letters. The mean annual rate of decline in vision with ranibizumab treatment was 3.3 letters and 2.3 letters after switching to aflibercept.

Conclusions : In this well defined group of patients with nAMD non-rensponsive to ranibizumab switching to aflibercept did not improve vision but may reduce treatment burden.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×